The latest research result, the immune score test, can now more accurately define the disease progression of colon cancer patients. According to an international study of more than 2,500 patients, immune scores have been shown to be effective in predicting which patients have a high risk of tumor recurrence and can benefit from intensive treatment after surgery.
Hukuru hwegomarara remukoloni hunofanirwa kuverengerwa zvakanyanya zvichienderana nekupararira kwayo uye metastasis mukoloni. Iyi fungidziro yehukasha hwegomarara uye njodzi yekudzokazve mushure mekurapwa inovandudza kurapwa. Kwemakumi emakore, zvave zvichitendwa kuti kudzivirira kwezvirwere zvevarwere kuchava nemhedzisiro inobatsira pagomarara. Tsvagiridzo yazvino inoratidza kuti kupindirwa kwemamota egomarara nemaseru anodzivirira muviri kunogona kuve chiratidzo chakanaka chegwaro rekukura kwegomarara re colorectal, ichiva chishandiso chinogoneka chekuzivisa masero edziviriro ane ruzivo rwakanyanya nezvekufambira mberi kwechirwere.
Kugadzirwa kweiyi immunological bvunzo kwakakodzera kuchipatara tsika. Inoshanda nekuyera kuwanda kwemasero maviri ekudzivirira mumarara uye margin awo ekupinda: akazara T masero (CD3 +) uye anouraya T masero (cytotoxic CD8 +). Ichi chidzidzo chakaongorora kukosha kwekufungidzira kwevarwere vane hombe yakakura kwazvo cancer, kusanganisira 2681 varwere vanobva munzvimbo dzakasiyana. Zvinoenderana nenjodzi yekudzokororazve (makore mashanu mushure mekuvhiyiwa) uye chiyero chekupona, varwere vakapatsanurwa kuita mapoka matatu (epamusoro, epakati nepasi) ezvirwere zvemuviri zvekufungidzira kuita kwekufungidzira. Mhedzisiro yacho inoratidza kuti varwere vane yakakwira immune zviyero vanopa iyo yakaderera njodzi yekudzokazve uye kwenguva yakareba yekupona.
Of the 700 patients, only 8% of patients with high scores relapsed after 5 years. However, the relapse rate of patients with middle and low scores increased significantly, reaching 19% and 32%, respectively. These findings indicate that the immune score provides an accurate and reliable assessment of the risk of colon cancer recurrence. Use the risk of recurrence to improve individual patient treatment strategies, especially changes in chemotherapy regimens. In view of the highly positive results of colon cancer, immunoscore tests for other cancers are under way, which will revolutionize the treatment of cancer patients.
